financetom
Business
financetom
/
Business
/
What's Going On With Trump Media & Technology Stock On Monday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Trump Media & Technology Stock On Monday?
Jun 24, 2024 5:30 AM

Trump Media & Technology Group Corp ( DJT ) , the operator of the Truth Social platform, is trading higher on Monday. Last week the company announced it expects to receive over $69.4 million from the cash exercise of warrants on June 20 and 21, 2024.

The cash exercise option became available after the Securities and Exchange Commission (SEC) declared the company’s registration statement effective on June 18, 2024,

TMTG revealed that if all warrants covered by the registration statement are exercised for cash, the company could receive up to approximately $247 million.

Additionally, the company will have $40 million of restricted cash become unrestricted due to the effectiveness of the registration statement. These funds add to the over $200 million in unrestricted cash already held by TMTG as of June 18, 2024.

The infusion of funds will likely support further development and expansion of its platforms, including Truth Social.

TMTG has experienced a significant decline in market value. The conservative social media company’s stock has dropped nearly 50% since May 30, following the conviction of former President Donald Trump on 34 felony counts in a hush money trial, CNN reports.

Despite the falling share price, experts warn that TMTG remains overvalued. Truth Social is a minor player in social media compared to platforms like Elon Musk's X, Reddit Inc ( RDDT ) , and Meta Platforms Inc ( META ) Instagram Threads.

Some experts compare TMTG to meme stocks like GameStop Corp ( GME ) and AMC Entertainment Holdings, Inc ( AMC ) , which trade on momentum rather than fundamentals.

Trump, the dominant shareholder with 114.75 million shares, has seen his stake’s value drop from $6 billion to about $3.1 billion since late May. The company plans to use the funds raised to enhance its ad platform and explore potential mergers and acquisitions.

TMTG stock gained 118% in the last 12 months.

Price Action: DJT shares are trading higher by 7.12% to $29.63 premarket at last check on Monday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Victoria's Secret says cyber incident led to temporary website shut down
Victoria's Secret says cyber incident led to temporary website shut down
Jun 3, 2025
June 3 (Reuters) - Victoria's Secret on Tuesday disclosed that it detected a security incident relating to information technology systems, which led to the lingerie maker temporarily shutting down its website for roughly three days. The company said it temporarily shut down its corporate systems and e-commerce website on May 26 and immediately enacted response protocols to attempt to contain...
BRIEF-Heidelberg Materials North America Has Acquired Certain Assets Of Concrete Crushers Inc. (CCI)
BRIEF-Heidelberg Materials North America Has Acquired Certain Assets Of Concrete Crushers Inc. (CCI)
Jun 3, 2025
June 3 (Reuters) - HEIDELBERG MATERIALS AG: * HEIDELBERG MATERIALS NORTH AMERICA ANNOUNCED TODAY THAT IT HAS ACQUIRED CERTAIN ASSETS OF CONCRETE CRUSHERS INC. (CCI) * TRANSACTION INCLUDES A RECYCLED AGGREGATES YARD IN SOUTHEAST CALGARY AND A CONTRACT CRUSHING BUSINESS WITH FOUR MOBILE PLANTS Source text: Further company coverage: (Gdansk Newsroom) ;)) ...
Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation
Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation
Jun 3, 2025
08:11 AM EDT, 06/03/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Tuesday that the US Food and Drug Administration has granted orphan drug designation to BEAM-101, an investigational cell therapy for sickle cell disease. The designation provides tax credits for development and a potential seven years of market exclusivity for the drug, which is currently being tested in...
COLUMN-Rio Tinto bets lithium will retain its battery metal crown: Andy Home
COLUMN-Rio Tinto bets lithium will retain its battery metal crown: Andy Home
Jun 3, 2025
LONDON, June 3 (Reuters) - It's a tough time to be a lithium producer as the light metal sinks under the weight of excess supply. Lithium hydroxide prices have collapsed by 90% from their 2022 peak and show no signs of recovery. Multiple producers are now operating at zero or negative margins, according to consultancy Wood Mackenzie. Even giants like...
Copyright 2023-2025 - www.financetom.com All Rights Reserved